S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

RVMD Revolution Medicines Inc

42.00

-2.42 (-5.45%)

11 Jan 2025 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Revolution Medicines (NASDAQ:RVMD)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Revolution Medicines Charts.

Revolution Medicines (NASDAQ:RVMD)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Revolution Medicines Charts.

Revolution Medicines Inc News

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
Tuesday 7 January 2025 (5 days ago) • GlobeNewswire Inc.

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Friday 6 December 2024 (1 month ago) • GlobeNewswire Inc.

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Wednesday 4 December 2024 (1 month ago) • GlobeNewswire Inc.

Revolution Medicines Announces Commencement of Public Offering of Common Stock
Tuesday 3 December 2024 (1 month ago) • GlobeNewswire Inc.

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Monday 2 December 2024 (1 month ago) • GlobeNewswire Inc.

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
Thursday 28 November 2024 (1 month ago) • GlobeNewswire Inc.

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
Thursday 7 November 2024 (2 months ago) • GlobeNewswire Inc.

Revolution Medicines to Participate in Upcoming Investor Conferences
Wednesday 6 November 2024 (2 months ago) • GlobeNewswire Inc.

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
Thursday 31 October 2024 (2 months ago) • GlobeNewswire Inc.

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Friday 25 October 2024 (3 months ago) • GlobeNewswire Inc.

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Wednesday 23 October 2024 (3 months ago) • GlobeNewswire Inc.

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Tuesday 22 October 2024 (3 months ago) • GlobeNewswire Inc.

More Revolution Medicines Inc News Articles

Commonwealth Bank Of Aus...

S&P ASX 300 Metals and M...

Newcrest Mining

Australian SE All Ordina...

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions